Product Description: Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Kristen L Nowak, et al. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2020 Dec 4;2(2):224-235./[2]Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140.
CAS Number: 2226654-05-1
Molecular Weight: N/A
Compound Purity: 99.75
Research Area: Inflammation/Immunology; Cardiovascular Disease